Is Immatics Biotechnologies Stock a Good Investment?
Immatics Biotechnologies Investment Advice | IMTXW |
- Examine Immatics Biotechnologies' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Immatics Biotechnologies' leadership team and their track record. Good management can help Immatics Biotechnologies navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Immatics Biotechnologies' business and its evolving consumer preferences.
- Compare Immatics Biotechnologies' performance and market position to its competitors. Analyze how Immatics Biotechnologies is positioned in terms of product offerings, innovation, and market share.
- Check if Immatics Biotechnologies pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Immatics Biotechnologies' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in immatics biotechnologies GmbH stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if immatics biotechnologies GmbH is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Immatics Biotechnologies Stock
Researching Immatics Biotechnologies' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years.
To determine if Immatics Biotechnologies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immatics Biotechnologies' research are outlined below:
| Immatics Biotechnologies generated a negative expected return over the last 90 days | |
| Immatics Biotechnologies has high historical volatility and very poor performance | |
| Immatics Biotechnologies has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 54 M. Net Loss for the year was (96.99 M) with loss before overhead, payroll, taxes, and interest of (23.99 M). |
Immatics Biotechnologies' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 673 M.Immatics Biotechnologies' profitablity analysis
The company has Profit Margin (PM) of (0.48) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.01 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.01.Determining Immatics Biotechnologies' profitability involves analyzing its financial statements and using various financial metrics to determine if Immatics Biotechnologies is a good buy. For example, gross profit margin measures Immatics Biotechnologies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immatics Biotechnologies' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Immatics Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of immatics biotechnologies GmbH. Check Immatics Biotechnologies' Beneish M Score to see the likelihood of Immatics Biotechnologies' management manipulating its earnings.
Basic technical analysis of Immatics Stock
As of the 29th of March, Immatics Biotechnologies retains the Risk Adjusted Performance of (0.02), market risk adjusted performance of (0.53), and Standard Deviation of 29.31. Immatics Biotechnologies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Immatics Biotechnologies variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Immatics Biotechnologies is priced fairly, providing market reflects its last-minute price of 0.0151 per share. As Immatics Biotechnologies appears to be a penny stock we also urge to confirm its jensen alpha numbers.Understand Immatics Biotechnologies' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Immatics Biotechnologies' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 20.12 | |||
| Coefficient Of Variation | (2,904) | |||
| Standard Deviation | 29.31 | |||
| Variance | 859.32 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.92) | |||
| Total Risk Alpha | 0.8189 | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 131.73 | |||
| Value At Risk | (40.00) | |||
| Potential Upside | 48.51 | |||
| Skewness | 1.18 | |||
| Kurtosis | 2.17 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.53) | |||
| Mean Deviation | 20.12 | |||
| Coefficient Of Variation | (2,904) | |||
| Standard Deviation | 29.31 | |||
| Variance | 859.32 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.92) | |||
| Total Risk Alpha | 0.8189 | |||
| Treynor Ratio | (0.54) | |||
| Maximum Drawdown | 131.73 | |||
| Value At Risk | (40.00) | |||
| Potential Upside | 48.51 | |||
| Skewness | 1.18 | |||
| Kurtosis | 2.17 |
Consider Immatics Biotechnologies' intraday indicators
Immatics Biotechnologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immatics Biotechnologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immatics Biotechnologies time-series forecasting models is one of many Immatics Biotechnologies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immatics Biotechnologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immatics Stock media impact
Far too much social signal, news, headlines, and media speculation about Immatics Biotechnologies that are available to investors today. That information is available publicly through Immatics media outlets and privately through word of mouth or via Immatics internal channels. However, regardless of the origin, that massive amount of Immatics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immatics Biotechnologies news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immatics Biotechnologies relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immatics Biotechnologies' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immatics Biotechnologies alpha.
Immatics Biotechnologies Corporate Management
| Andrea Mokler | VP Sciences | Profile | |
| Miriam Meyer | VP Affairs | Profile | |
| Edward Sturchio | General Secretary | Profile | |
| Arnd MBA | Chief Officer | Profile | |
| Toni Weinschenk | CoFounder Officer | Profile | |
| Thomas Ulmer | Chief Officer | Profile |
Additional Tools for Immatics Stock Analysis
When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.